regardless of promising clinical evidence, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing substantial resistance from managed care entities. Such companies are frequently creating barriers to coverage, such as steep cost criteria and PA that hinder consumer opportunity. Market suggest that